Du Huihui, Wei Zhiyun, Yan Yucai, Xiong Yuyu, Zhang Xiaoqing, Shen Lu, Ruan Yunfeng, Wu Xi, Xu Qingqing, He Lin, Qin Shengying
Bio-X Institutes, Shanghai Jiao Tong UniversityShanghai, China; Shanghai Genome Pilot Institutes for Genomics and Human HealthShanghai, China.
Department of Pharmacy, Shanghai Pulmonary Hospital Shanghai, China.
Front Pharmacol. 2016 Apr 25;7:98. doi: 10.3389/fphar.2016.00098. eCollection 2016.
Variability in activity of CYP2C9, which is involved in the metabolism of approximately 15% of current therapeutic drugs, is an important contributor to interindividual differences in drug response. To evaluate the functional alternations of CYP2C9()2, CYP2C9()3, CYP2C9()8, CYP2C9()11 and CYP2C9(*)31, identified in our previous study in Chinese Han population, allelic variants as well as the wild-type CYP2C9 were transiently expressed in COS-7 cells. Kinetic parameters (Km, Vmax, and Clint) for S-warfarin 7-hydroxylation by these recombinant CYP2C9s were determined. Relative to CYP2C9.1, recombinant CYP2C9.3 and CYP2C9.11 exhibited significantly higher Km values, and all allelic variants showed significantly decreased Vmax and Clint values. Among all allelic variants, catalytic activity of CYP2C9.3 and CYP2C9.11 reduced the most (8.2% and 9.8% of Clint ratio, respectively; P < 0.001). These findings should be useful for predicting the phenotype profiles of CYP2C9 in Chinese Han population, comparing the functional results of these alleles accurately, and finally optimizing pharmacotherapy of drug treatment.
CYP2C9参与了约15%的现有治疗药物的代谢,其活性的变异性是药物反应个体差异的一个重要因素。为了评估在我们之前对中国汉族人群的研究中鉴定出的CYP2C9()2、CYP2C9()3、CYP2C9()8、CYP2C9()11和CYP2C9(*)31等位基因变体以及野生型CYP2C9的功能改变,将它们在COS-7细胞中瞬时表达。测定了这些重组CYP2C9对S-华法林7-羟基化的动力学参数(Km、Vmax和Clint)。相对于CYP2C9.1,重组CYP2C9.3和CYP2C9.11表现出显著更高的Km值,并且所有等位基因变体均表现出显著降低的Vmax和Clint值。在所有等位基因变体中,CYP2C9.3和CYP2C9.11的催化活性降低最多(Clint比值分别为8.2%和9.8%;P < 0.001)。这些发现对于预测中国汉族人群中CYP2C9的表型特征、准确比较这些等位基因的功能结果以及最终优化药物治疗的药物疗法应该是有用的。